The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).
Teresa M. Petrella
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Catalin Liviu Dragos Mihalcioiu
No relevant relationships to disclose
Elaine McWhirter
No relevant relationships to disclose
Karl Belanger
No relevant relationships to disclose
Kerry J. Savage
No relevant relationships to disclose
Xinni Song
No relevant relationships to disclose
Omid Hamid
No relevant relationships to disclose
Tina Cheng
No relevant relationships to disclose
Mary L. Davis
No relevant relationships to disclose
Christopher W Lee
No relevant relationships to disclose
Alan Spatz
No relevant relationships to disclose
Jose Gerard Monzon
No relevant relationships to disclose
Linda Hagerman
No relevant relationships to disclose
Bingshu E Chen
No relevant relationships to disclose
Janet Dancey
No relevant relationships to disclose